Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Income: 2016-2025

Historic Net Income for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.

  • UroGen Pharma's Net Income fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
  • As of Q3 2025, UroGen Pharma's Net Income stood at -$33.3 million, which was up 33.23% from -$49.9 million recorded in Q2 2025.
  • UroGen Pharma's Net Income's 5-year high stood at -$21.9 million during Q3 2023, with a 5-year trough of -$49.9 million in Q2 2025.
  • Its 3-year average for Net Income is -$32.4 million, with a median of -$32.3 million in 2024.
  • In the last 5 years, UroGen Pharma's Net Income skyrocketed by 30.62% in 2021 and then tumbled by 49.51% in 2025.
  • UroGen Pharma's Net Income (Quarterly) stood at -$28.5 million in 2021, then declined by 1.47% to -$28.9 million in 2022, then grew by 9.88% to -$26.0 million in 2023, then tumbled by 44.19% to -$37.5 million in 2024, then crashed by 40.87% to -$33.3 million in 2025.
  • Its last three reported values are -$33.3 million in Q3 2025, -$49.9 million for Q2 2025, and -$43.8 million during Q1 2025.